In lieu of an abstract, here is a brief excerpt of the content:

Worldwide medi­ cation consumption has expanded significantly in recent de­ cades, particularly in Western socie­ ties, such as France, the United Kingdom, and the United States, and in rapidly developing middle-­ income countries , including China, Brazil, and India (Busfield 2010). For example, worldwide prescription drug sales nearly tripled between the early 1980s and 2002, reaching a figure of US$400 billion (Angell 2005). Moreover, worldwide sales grew from US$350 billion in 2000 to US$700 billion by 2007, a doubling in the span of seven years (Busfield 2010). As this pertains to medi­ cations for attention deficit–­ hyperactivity disorder (ADHD), while American consumption skyrocketed during the 1980 and 1990s (Drug Enforcement Agency 1981–2006), in recent de­ cades significant increases have also occurred in other countries. According to the International Narcotics Control Board (INCB), a UN agency charged with tracking the consumption of controlled substances, between 2000 and 2012, Switzerland’s methylphenidate (the generic form of Ritalin) consumption grew 422% (from 2.79 to 14.7 standard doses per 1,000 inhabitants), Iceland’s grew 529% (from 2.29 to 14.8 standard doses), and Israel’s grew 1,077% (from 0.58 to 8.48 standard doses) (for more details, see ­ table 14.1). Sociologists (Abraham 2010; Busfield 2015) view such increases as evidence of the pharmaceuticalization of society, “the pro­ cess 14 Pharmaceuticalization through Government Funding Activities ADHD in New Zealand Manuel Vallée ­ T able 14.1. Methylphenidate Use by Country (standard daily dose per 1,000 inhabitants/day) Rank 2012 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 1 Iceland 2.29 2.35 3.56 5.27 7.53 7.91 4.53 10.6 11.15 11.25 4.72 14.07 14.8 2 Switzerland 2.79 2.82 2.72 2.23 1.97 1.36 3.66 2.36 3.44 3.58 n/a n/a 14.72 3 Israel 0.58 0.72 0.97 1.31 1.62 2.69 2.26 3.13 4.45 6.05 7.38 7.4 8.48 4 United States 3.69 5.11 5.88 5.21 7.14 7.61 9.18 5.21 12.03 9.3 15.5 19.93 7.94 5 Sweden 0.1 0.16 0.21 0.35 0.58 0.89 1.59 1.72 2.51 3.53 4.92 6.22 7.19 6 Norway 0.74 0.78 0.95 2.13 2.23 2.61 3.66 4.38 4.4 5.9 n/a n/a 6.94 7 Denmark n/a 0.22 0.27 1.77 0.63 0.88 1.3 1.77 3.55 2.79 5.09 5.88 6.37 8 Canada 4.74 0.29 1.59 4.24 4.22 2.55 4 5.42 6.12 2.07 n/a n/a 5.51 9 Spain 0.24 0.66 0.55 0.78 0.49 1.11 1.26 0.02 1.18 1.49 n/a n/a 2.82 10 New Zealand 1.72 1.29 1.54 1.23 1.93 1.35 1.35 1.75 1.79 n/a n/a n/a 2.70 11 Belgium 0.47 0.51 0.79 1.12 0.99 1.24 1.45 1.93 2.06 1.97 n/a n/a 2.54 12 Australia 0.99 0.89 0.79 1.34 1 1.44 1.36 1.39 1.53 1.78 n/a n/a 2.33 13 Germany 0.56 0.67 0.78 0.99 1.11 1.47 1.39 1.92 2.19 2.07 1.98 1.97 2.08 14 Chile 0.15 0.24 0.22 0.35 0.33 0.44 0.53 0.75 n/a 1.13 1.1 1.54 1.70 15 Finland 0.04 0.07 0.07 0.29 0.33 0.57 0 0.54 n/a 1.56 n/a n/a 1.47 16 South Africa n/a 0.16 0.23 0.27 0.11 0.51 0.3 0 n/a n/a n/a n/a 1.02 17 United Kingdom 1.31 1.04 1.35 0.95 1.38 1.32 0 0.01 3.67 0.39 0.15 0.5 0.68 18 Netherlands 0.99 1.11 1...

pdf

Additional Information

ISBN
9781421423807
Related ISBN
9781421423791
MARC Record
OCLC
1012344532
Pages
384
Launched on MUSE
2018-01-03
Language
English
Open Access
No
Back To Top

This website uses cookies to ensure you get the best experience on our website. Without cookies your experience may not be seamless.